783P Impact of cemiplimab on quality of life (QoL), functioning and symptoms in patients (pts) with recurrent/metastatic (R/M) cervical carcinoma: Results from EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9

• DOI: 10.1016/j.annonc.2021.08.1225
• Publication Date: 2021-09-21T19:01:34Z
• Authors: A. Oaknin; B.J. Monk; I. Vergote; A.C. de Melo; Y.M. Kim; A. Lisyanskaya; V. Samouëlian; H.S. Kim; E.A. Gotovkin; F. Damian; C-L. Chang; S. Takahashi; J. Li; M. Mathias; M.G. Fury; C. Ivanescu; M. Reaney; J. Harnett; C-I. Chen; K.S. Tewari
• Keywords: 03 medical and health sciences; 0302 clinical medicine